Schjesvold FH, Dimopoulos MA, Delimpasi S, Robak P, Coriu D, Legiec W, Pour L, Špička I, Masszi T, Doronin V, Minarik J, Salogub G, Alekseeva Y, Lazzaro A, Maisnar V, Mikala G, Rosiñol L, Liberati AM, Symeonidis A, Moody V, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Hájek R et al. (2022)
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
Lancet Haematol (in press)
DOI 10.1016/S2352-3026(21)00381-1, PubMed 35032434

Ng S, Rodger MA, Ghanima W, Kovacs MJ, Shivakumar S, Kahn SR, Sandset PM, Kearon C, Mallick R, Delluc A (2022)
External validation of the patient reported Villalta scale for the diagnosis of post-thrombotic syndrome
Thromb Haemost (in press)
DOI 10.1055/a-1738-1313, PubMed 35021257

Arvanitakis A, Holme PA, Berntorp E, Astermark J (2022)
Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81-8973
Haemophilia
DOI 10.1111/hae.14489, PubMed 35005818